Neem recently had the pleasure of attending the 40th European Cystic Fibrosis Conference that took place in the sunny Spanish climes of Seville from the 7th to the 10th June. The conference brought together a mix of fundamental science, clinical and practically oriented talks from within the European and North American CF communities. Neem’s visit was an opportunity to share a snapshot of our work around development of NX-AS-401, our lead candidate. This adjunct to existing antimicrobials looks to have promise in controlling chronic lung infection caused by Pseudomonas aeruginosa.